© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
December 07, 2021
In a review, Sandoz researchers discuss lingering barriers that prevent insulin prices from falling to more affordable levels.
December 06, 2021
December 05, 2021
December 03, 2021
December 02, 2021
November 21st 2021
The utilization rates for biosimilars in community oncology have been much higher than for other disease categories and are only expected to rise, says Steven Yates, MD.
November 20th 2021
By Tony Hagen
Stakeholder education programs and robust data on clinical studies are key to building patient and provider support for biosimilars, according to a new whitepaper.
November 19th 2021
Here are the top 5 biosimilar articles for the week of November 15, 2021.
November 18th 2021
By Meir Rinde, MS
European Medicines Agency (EMA) officials said their pilot was based on wrong assumptions about the biosimilar development process.
November 17th 2021
The World Health Organization (WHO) has issued a fresh draft of its biosimilar evaluation guidelines. Medicines for Europe science and policy expert Marta Baldrighi, PhD, explains the significance.
November 16th 2021
The Institute for Clinical and Economic Review (ICER) states in its latest Unsupported Price Increase report that when it comes to rising drug prices, Humira is in a class of its own.
The conservative think tank Pacific Research Institute (PRI) calculated potential biosimilar savings across multiple market share scenarios.
November 15th 2021
Martin Perry, MBChB, BSc, MMEd, FRCP, clinical medical director for the National Health Service in Greater Glasgow and Clyde, Scotland, explains frontline care with biosimilars during COVID-19.
November 14th 2021
Steven Yates, MD, explains how the relationships that nurses have with patients can influence biosimilar acceptance.
November 13th 2021
Kathy Oubre, MS, a cochair of the biosimilars committee of the Community Oncology Alliance (COA), explains findings from a broad study of biosimilar use in oncology practices.